The landscape of Zantac litigation has undergone significant shifts following recent legal developments. On July 10, 2025, the Delaware Supreme Court unanimously ruled that nearly 75,000 plaintiffs could not introduce expert testimony alleging that the heartburn medication Zantac caused their cancer. The court found that the trial judge had improperly allowed expert opinions without ensuring they met rigorous scientific reliability standards. Justice Abigail LeGrow emphasized that the lower court erred by presuming the admissibility of expert testimony despite methodological flaws. This decision aligns with a 2022 federal ruling in Florida that also excluded similar expert testimony in Zantac-related cases. ([reuters.com](https://www.reuters.com/legal/litigation/delaware-supreme-court-sides-with-zantac-drugmakers-over-evidence-2025-07-10/?utm_source=openai))
Zantac, approved by U.S. regulators in 1983, became the world’s best-selling medicine within five years. However, in 2020, the U.S. Food and Drug Administration requested the removal of all ranitidine-based products from the market due to concerns that ranitidine could degrade into the probable carcinogen NDMA over time and when exposed to heat. Despite the recall, drugmakers have maintained that no reliable evidence links Zantac to cancer. ([reuters.com](https://www.reuters.com/legal/litigation/delaware-supreme-court-sides-with-zantac-drugmakers-over-evidence-2025-07-10/?utm_source=openai))
In October 2024, GlaxoSmithKline (GSK) reached agreements with ten plaintiff firms, representing approximately 80,000 claimants, to resolve U.S. state court product liability cases for up to $2.2 billion. This settlement, which does not admit liability, is expected to be fully implemented by mid-2025. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1131399/000113139925000007/R54.htm?utm_source=openai))
The Delaware Supreme Court’s recent decision is seen as preserving the state’s reputation as a business-friendly jurisdiction by setting a high bar for expert testimony in mass tort cases. This ruling, coupled with the lack of plaintiff verdicts, raises questions about the future viability of Zantac lawsuits. While some litigation continues, the exclusion of expert testimony and the trend of defense verdicts suggest a challenging path ahead for plaintiffs seeking to prove causation between Zantac and cancer. ([reuters.com](https://www.reuters.com/legal/litigation/delaware-supreme-court-sides-with-zantac-drugmakers-over-evidence-2025-07-10/?utm_source=openai))